GlassScriptPhysician profile
Chandos D Tackett
NPI 1912933151
$11,694.45
in general payments reported to CMS, 2019-2025
47 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,614 · 2020: $987 · 2021: $597 · 2022: $843 · 2023: $2,099 · 2024: $2,423 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,653.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,315.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,212.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $1,187.83 | 2019-2025 | |
| Abbvie INC. | $1,084.57 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $936.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $774.55 | 2019-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $655.98 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $645.80 | 2019-2025 | |
| Amgen INC. | $394.05 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.20 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $323.78 | 2019-2024 | Jynarque, Rexulti |
| Esperion Therapeutics, INC. | $288.12 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $285.06 | 2019-2022 | |
| Amarin Pharma, INC. | $260.12 | 2019-2020 | |
| Shield Therapeutics INC | $222.83 | 2023-2024 | Accrufer |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $216.10 | 2022-2025 | Nuzyra |
| Avanir Pharmaceuticals, INC. | $206.40 | 2019 | |
| Argenx US, INC. | $158.03 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Dexcom, INC. | $127.38 | 2023-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.86 | 2022-2024 | |
| Vifor Pharma, INC. | $64.79 | 2022-2023 | Veltassa, Korsuva |
| Teva Pharmaceuticals USA, INC. | $62.99 | 2020-2023 | Ajovy |
| Sanofi-Aventis U.S. LLC | $54.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $52.69 | 2019-2023 | Seglentis, Livalo |
| Abbott Laboratories | $42.18 | 2022 | |
| Alexion Pharmaceuticals, INC. | $40.94 | 2023 | Ultomiris |
| Halozyme INC | $40.17 | 2023 | |
| Antares Pharma, INC. | $38.65 | 2023 | Tlando, Xyosted, Nocdurna |
| Allergan, INC. | $38.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.82 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $32.61 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $27.78 | 2023 | Yupelri |
| Philips North America LLC | $23.38 | 2024 | (5044) Mcot |
| Medtronic USA, INC. | $18.50 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.15 | 2023 | Rebyota |
| Exact Sciences Corporation | $17.58 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $17.44 | 2023 | Injectafer |
| Genentech USA, INC. | $16.41 | 2020 | |
| Sanofi Pasteur INC. | $16.23 | 2019 | |
| Boston Scientific Corporation | $14.40 | 2024 | Watchman Flx |
| Incyte Corporation | $14.12 | 2024 | Opzelura |
| Abiomed | $14.12 | 2025 | |
| Intercept Pharmaceuticals, INC. | $13.73 | 2020 | |
| Sumitomo Pharma America, INC. | $13.24 | 2024 | Gemtesa |
| Melinta Therapeutics, LLC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandos Tackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.